Can Quetiapine (Seroquel) Cause Acute Pancreatitis?
Yes, quetiapine can cause acute pancreatitis, and this is a recognized adverse effect documented in the FDA drug label and supported by multiple recent pharmacovigilance studies showing a 30-fold increased risk compared to other medications.
FDA-Recognized Adverse Effect
The FDA drug label for Seroquel explicitly lists pancreatitis as a postmarketing adverse reaction temporally related to quetiapine therapy 1. This establishes quetiapine-induced pancreatitis as a documented, though rare, serious adverse effect that clinicians must recognize.
Magnitude of Risk
Recent pharmacovigilance data quantifies this risk more precisely:
- Quetiapine carries approximately a 30-fold increased risk of pancreatitis compared to other medications (proportional reporting ratio: 30.708, reporting odds ratio: 32.990) 2
- Among multi-acting receptor-targeted antipsychotics (MARTA), quetiapine shows an adjusted sequence ratio of 2.31 (95% CI: 2.27-2.34) for pancreatitis risk 3
- This risk is lower than clozapine (ASR 6.04) and olanzapine (ASR 3.08), but still clinically significant 3
Clinical Presentation and Timing
Median time from quetiapine initiation to pancreatitis onset is 613 days (approximately 20 months), indicating this typically occurs with prolonged therapy rather than acute exposure 3. However, cases have been reported with exposures ranging from 5 days to over 10 years 4.
Key Clinical Features:
- Presents identically to pancreatitis from other causes (abdominal pain, nausea, vomiting)
- Median lipase elevation: 1210 IU/L (range 243-5482 IU/L) 4
- Most cases are mild (63%), but 27% are severe and 10% can be fatal 4
- Rapid clinical improvement typically occurs upon drug discontinuation 5
High-Risk Populations
Exercise particular caution in patients with:
- Age ≤65 years and weight >80 kg (identified risk factors) 6
- Pre-existing metabolic conditions (obesity, diabetes, dyslipidemia) 3
- Concomitant medications associated with pancreatitis (present in 80% of cases) 4
- Antipsychotic polypharmacy (associated with 53% of cases) 4
Mechanism
While quetiapine-induced pancreatitis is often attributed to metabolic derangements (hypertriglyceridemia, diabetic ketoacidosis), cases occur independent of these metabolic factors, suggesting direct drug toxicity as an alternative mechanism 5. Network toxicology analysis suggests quetiapine may exert toxic effects through specific hub gene interactions 6.
Critical Clinical Pitfalls
Don't assume metabolic causes are required: Pancreatitis can occur via direct toxicity even without hypertriglyceridemia or hyperglycemia 5
Consider recurrent episodes: Patients may experience multiple episodes during long-term therapy, suggesting cumulative toxicity 5
Evaluate polypharmacy carefully: Most cases involve concomitant medications (mood stabilizers, other antipsychotics) that may contribute to risk 4
Don't overlook in elderly patients: Despite younger mean age in case series (39 years), elderly patients on long-term therapy remain at risk 5
Diagnostic Approach When Suspected
When a patient on quetiapine presents with abdominal pain:
- Measure lipase (preferred over amylase) for diagnosis 7
- Obtain contrast-enhanced CT if diagnosis uncertain 7
- Systematically exclude common causes: gallstones (ultrasound), alcohol use, hypertriglyceridemia, hypercalcemia 5
- Review all concomitant medications for pancreatitis associations 4
- Calculate Naranjo probability score to assess drug causality 4
Management Recommendations
Discontinue quetiapine immediately if pancreatitis is diagnosed and no other clear etiology is identified 5. The temporal relationship between drug withdrawal and clinical improvement supports causality. Provide supportive care per standard pancreatitis guidelines: aggressive fluid resuscitation with isotonic crystalloids, oxygen supplementation to maintain saturation >95%, and appropriate monitoring 8.
Do not rechallenge with quetiapine after an episode of suspected drug-induced pancreatitis, as recurrence risk is substantial 5.